Pradžia › Šlapimo pūslės vėžys
Šlapimo pūslės vėžys klinikiniai tyrimai JAV ieško dalyvių
142 tyrimai dėl Šlapimo pūslės vėžys ieško dalyvių vietose visoje Jungtinėse Valstijose.
Miestai su daugiausia tyrimų
- New York City, NY35 tyrimai
- Nashville, TN31 tyrimas
- Houston, TX31 tyrimas
- Dallas, TX27 tyrimai
- Boston, MA26 tyrimai
- Washington, DC26 tyrimai
- Los Angeles, CA24 tyrimai
- Baltimore, MD24 tyrimai
- St. Louis, MO22 tyrimai
- Philadelphia, PA21 tyrimas
- Seattle, WA21 tyrimas
- Edison, NJ21 tyrimas
- Chicago, IL21 tyrimas
- Durham, NC20 tyrimai
- Columbus, OH19 tyrimai
- Cleveland, OH18 tyrimai
- Atlanta, GA16 tyrimai
- Queens, NY16 tyrimai
- Baldwin Park, CA14 tyrimai
- San Francisco, CA13 tyrimai
- Portland, OR13 tyrimai
- San Antonio, TX13 tyrimai
- Rochester, MN12 tyrimai
- Kansas City, KS12 tyrimai
- Austin, TX12 tyrimai
- Orange, CA12 tyrimai
- Grand Rapids, MI12 tyrimai
- San Diego, CA11 tyrimai
- Birmingham, AL11 tyrimai
- Milwaukee, WI11 tyrimai
- Denver, CO11 tyrimai
- Detroit, MI11 tyrimai
- Irvine, CA11 tyrimai
- Staten Island, NY11 tyrimai
- New Rochelle, NY11 tyrimai
- Minneapolis, MN11 tyrimai
- Oklahoma City, OK11 tyrimai
- Kansas City, MO10 tyrimai
- Omaha, NE10 tyrimai
- Myrtle Beach, SC10 tyrimai
Pagal valstiją
- Aidahas6 tyrimai
- Ajova12 tyrimai
- Alabama11 tyrimai
- Aliaska3 tyrimai
- Arizona20 tyrimai
- Arkansas15 tyrimai
- Delaveras4 tyrimai
- Džordžija19 tyrimai
- Florida38 tyrimai
- Ilinoisas30 tyrimai
- Indianas14 tyrimai
- Kalifornija54 tyrimai
- Kanzasas17 tyrimai
- Kentukis7 tyrimai
- Koloradas20 tyrimai
- Kolumbijos apskritis17 tyrimai
- Konektikutas9 tyrimai
- Luiziana13 tyrimai
- Masčusetsas31 tyrimas
- Merilendas36 tyrimai
- Minesota24 tyrimai
- Misisipė3 tyrimai
- Misūris27 tyrimai
- Mičiganas25 tyrimai
- Montana7 tyrimai
- Naujoji Hampšyras3 tyrimai
- Nebraska11 tyrimai
- Nevada5 tyrimai
- New Jersey26 tyrimai
- New Mexico3 tyrimai
- New York41 tyrimas
- North Carolina26 tyrimai
- North Dakota4 tyrimai
- Ohio36 tyrimai
- Oklahoma12 tyrimai
- Oregon14 tyrimai
- Pennsylvania27 tyrimai
- Rhode Island4 tyrimai
- South Carolina16 tyrimai
- South Dakota4 tyrimai
- Tennessee34 tyrimai
- Texas51 tyrimas
- Utah14 tyrimai
- Vermont3 tyrimai
- Virginia24 tyrimai
- Washington25 tyrimai
- West Virginia5 tyrimai
- Wisconsin17 tyrimai
- Wyoming4 tyrimai
Nesenai atnaujinti tyrimai
Oficialus tyrimo tekstas (anglų kalba)
Evaluation for NCI Surgery Branch Clinical Research Protocols
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT00001823A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06465069KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT07232602En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 120 · Visoms lytims · Atnaujinta 2026-10-02 · NCT04235764Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT07000084Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 40 iki 75 · Visoms lytims · Atnaujinta 2026-10-02 · NCT05334069Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06770582A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06760819Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Renkami dalyviai4 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT06764095A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT06833073A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT06172478A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT07090499Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT06263153Imaging Study of [89Zr]DFO-YS5 for Cancer Detection
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT07664397Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT07061964Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT06470282Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT06394570Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT07667335Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius 2 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT00026884Patient-Centered Surgical Prehabilitation
Renkami dalyviaiLaukiami sveiki savanoriai
Amžius nuo 18 iki 85 · Visoms lytims · Atnaujinta 2026-09-30 · NCT05715684The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT07285044Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT07566156Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT03866382DK222 Study at Hopkins
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-29 · NCT07140315Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT07421700Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.